UK-based Horizon Discovery, a company backed by the University of Cambridge’s Enterprise Fund, has completed an initial public offering raising £68.6m ($114m) from institutional investors comprising £40m ($66m) for the Company before expenses and the sale of £28.6m ($47.6) of Sale Shares.
Horizon Discovery is a life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines. They are listed on London’s Aim, formerly the alternative investment market, under ticker symbol HZD.
Shares were…
